JENA, Germany, March  18, 2026  (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral

IFRX

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

InflaRx to Present Key Phase 3 Data at AAD 2026 Meeting

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>JENA, Germany, March  18, 2026  (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>InflaRx N.V. announced a late-breaking oral presentation of Phase 3 data for vilobelimab, focusing on its treatment for pyoderma gangrenosum, at the 2026 AAD Annual Meeting. This could significantly influence investor sentiment and perceptions of the company&#039;s pipeline potential.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>InflaRx will present Phase 3 data on vilobelimab at AAD 2026.</li><li>The presentation covers pyoderma gangrenosum and C5a/C5aR inhibition.</li><li>InflaRx focuses on anti-inflammatory therapeutics targeting C5a.</li><li>The AAD meeting runs from March 27-31, 2026, in Denver.</li><li>Data presentation may enhance investor outlook on InflaRx.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>InflaRx N.V. (IFRX)</strong>: Key presentation could impact stock performance positively.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits into &#039;Corporate Developments&#039; as it highlights a significant presentation that could affect the company&#039;s valuation and market perception based on clinical results.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Presentation outcomes could influence market sentiment for IFRX shares.</li><li>Positive Phase 3 data may attract new investments.</li><li>Interest in C5a therapies could escalate post-presentation.</li><li>Engagement with dermatology experts may validate IFRX&#039;s strategy.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>InflaRx will present on March 28, 2026, at 2:24 PM MT.</li><li>Presentation location: Bellco Theatre 3, Denver, CO.</li><li>The study involves a multicenter, randomized, placebo-controlled Phase 3 trial.</li><li>Vilobelimab targets ulcerative pyoderma gangrenosum.</li><li>InflaRx&#039;s lead program is izicopan, an orally administered small molecule.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider a bullish position on IFRX leading up to the AAD presentation.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">JENA, Germany, March  18, 2026  (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/IFRX">IFRX</a>), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The meeting will be held March 27-31, 2026, in Denver, CO. </p>  <p align="justify"><strong>Camilla Chong, MD, Chief Medical Officer of InflaRx, said: </strong>"It is an honor that our Phase 3 study data for vilobelimab in pyoderma gangrenosum (PG) have been selected for a late-breaking oral presentation at AAD. We look forward to engaging with the dermatology community on these critical findings in PG and our development program targeting the role of C5a/C5aR inhibition in other chronic immuno-inflammatory diseases."</p>  <p align="justify"><strong><u>AAD 2026 Late-Breaking Presentation Details</u></strong> <br></br><strong>Title:</strong> Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial</p>  <p align="justify"><strong>Session Type: </strong>Oral presentation<br></br><strong>Presenter: </strong>Benjamin Kaffenberger, MD <br></br><strong>Time:</strong> March 28, 2026, 2:24-2:36 PM MT<br></br><strong>Location:</strong> Bellco Theatre 3</p>  <p align="justify"><strong><em>About InflaRx</em></strong><br></br>InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/IFRX">IFRX</a>) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.</p>  <p align="justify">InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit <a href="https://www.globenewswire.com/Tracker?data=-_t2sHsiN8ZsMHvkqR2DhNIWxI2Q9ocrxTMzuRkRUAPwDI9DX84R6BpAVZJbaNShtyIBXdZe8frY2z9rM0Hkpg==" rel="nofollow" target="_blank">www.inflarx.de</a>. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).</p>  <p align="justify"><strong><em>Contacts:</em></strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:40%; width:40%; min-width:40%;;text-align: justify ;  vertical-align: middle; vertical-align: top ; "><strong>InflaRx N.V.</strong></td><td style="max-width:60%; width:60%; min-width:60%;;text-align: justify ;  vertical-align: middle; vertical-align: top ; "><strong>MC Services AG</strong></td></tr><tr><td style="text-align: justify ;  vertical-align: middle; vertical-align: top ; ">Jan Medina, CFA<br></br>Vice President, Head of Investor Relations<br></br>Email: <a href="mailto:IR@inflarx.de" rel="nofollow" target="_blank">IR@inflarx.de</a></td><td style="text-align: justify ;  vertical-align: middle; vertical-align: top ; ">Katja Arnold, Laurie Doyle, Dr. Regina Lutz<br></br>Email: <a href="mailto:inflarx@mc-services.eu" rel="nofollow" target="_blank">inflarx@mc-services.eu</a> <br></br>Europe: +49 89-210 2280<br></br>U.S.: +1-339-832-0752</td></tr></table> <p align="justify"><strong>FORWARD-LOOKING STATEMENTS</strong><br></br>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue," among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading "Risk factors" and "Cautionary statement regarding forward looking statements" in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3NDMzOCM3NDkxNzY3IzIxOTQyNDE="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZGEyZGRlMDctN2Y2Yi00ODEyLTg0YjktZjQzYTJmNDEwM2YyLTEyMDU3OTQtMjAyNi0wMy0xOC1lbg==/tiny/InflaRx-N-V-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e017df5c-9a9b-4f4f-9a94-6c2eeb0400bc"><img src="https://ml.globenewswire.com/media/e017df5c-9a9b-4f4f-9a94-6c2eeb0400bc/small/inflarx-logo-png.png" border="0" width="150" height="78" alt="Primary Logo"></img></a></p>

InflaRx N.V. announced a late-breaking oral presentation of Phase 3 data for vilobelimab, focusing on its treatment for pyoderma gangrenosum, at the 2026 AAD Annual Meeting. This could significantly influence investor sentiment and perceptions of the company's pipeline potential.

inflarx-announces-late-breaker-oral-presentation-on-vilobelimab-phase-3-results-in-pyoderma-gangrenosum-at-2026-american-academy-of-dermatology-annual-meeting

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News